OTX-TP is a drug product candidate that is intended for insertion into the canaliculus to deliver travoprost to the ocular surface for up to 90 days without preservatives. The goal of OTX-TP is to deliver a continuous steady release of travoprost throughout the treatment period. Ocular Therapeutix is currently enrolling patients in a phase 3 trial with OTX-TP to evaluate the reduction of intraocular pressure connected to glaucoma and ocular hypertension.
Caution: NEW DRUG – OTX-TP is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
“OTX-TP may provide a transformative modality with the potential to change the current standard of care.”
– Antony Mattessich, President and CEO